Ampio pharmaceuticals receives approval from the drugs controller general of india (dcgi) to commence ap-019 phase ii study in india

Englewood, colo., sept. 21, 2021 /prnewswire/ --  ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the drugs controller general of india (dcgi) of the central drugs standard control organization (cdsco) in the phase ii ap-019 clinical trial in india.
AMPE Ratings Summary
AMPE Quant Ranking